ArticleOpen life sciences2026
Effects of artichoke extracts and probiotic on maternal immunological activation, valproic acid-induced oxidative stress, and gut leakiness in a rat model of autism.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maternal health during pregnancy is a leading factor influencing offspring risk. This study investigated whether postnatal dietary supplementation could reduce oxidative stress and gut leakiness in a rat model of autism spectrum disorder (ASD). Male rat pups were prenatally exposed to valproic acid (VPA) or lipopolysaccharide (LPS) to induce ASD-like conditions. A total of 54 offspring of Wistar albino rats were divided into nine groups to evaluate various postnatal treatments, including an artichoke-based prebiotic (AR), probiotics (Pro), and omega-3 fatty acids (ω3). The experimental design also included control groups (saline, VPA-only, and LPS-only), as well as a protective regimen in which AR was administered both prenatally and postnatally. Oxidative stress and gut permeability "leakiness" were assessed using Enzyme-Linked Immunosorbent Assay (ELISA). Prenatal exposure to VPA and LPS was associated with increased oxidative stress levels in brain homogenates, accompanied by a significant decrease in glutathione (GSH). Additionally, elevated plasma levels of gut permeability biomarkers were observed. In the VPA model, treatment with artichoke-derived prebiotics - administered either prenatally, postnatally, or in combination with probiotics - effectively improved oxidative stress markers, as evidenced by a significant increase in GSH levels. Conversely, similar interventions in the LPS-induced maternal immune activation model did not significantly ameliorate oxidative stress, although a modest increase in GSH levels was noted. Plasma levels of gut permeability biomarkers did not show significant improvement in either model following treatment with artichoke-derived probiotics alone or in combination with probiotics and omega-3 fatty acids. However, intestinal fatty acid-binding protein levels were significantly reduced in all treatment groups across both models. In contrast, lipopolysaccharide-binding protein (LBP) levels were not significantly reduced by artichoke extract monotherapy in either model, although combination therapy with probiotics and/or omega-3s led to significant reductions in LBP. These results support the use of both VPA and LPS as complementary models for studying ASD. The VPA model, characterized by direct and predictable neurotoxic effects, appears to be more suitable for evaluating preventive interventions. In contrast, the LPS model more accurately captures the complex immune-inflammatory mechanisms implicated in ASD, highlighting the need for broader and more individualized treatment strategies. The differing responses to artichoke-based interventions in these models underscore the importance of considering ASD etiology when designing dietary and microbiome-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.